Clinical management of infections caused by enterobacteriaceae that express extended-spectrum β-Lactamase and AmpC enzymes

Seminars in Respiratory and Critical Care Medicine

Volumn 36, Issue 1, 2015, Pages 56-73

  Harris, Patrick N A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

AmpC; Enterobacteriaceae; extended spectrum lactamase; therapy

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFEPIME; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; MECILLINAM; NITROFURANTOIN; PIVMECILLINAM; TEMOCILLIN; TIGECYCLINE;

ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; BETA LACTAMASE AMPC PRODUCING ENTEROBACTERIACEAE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HUMAN; INFECTION RISK; MOLECULAR EPIDEMIOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR;

EID: 84964311442     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0034-1398387     Document Type: Article

References (222)

1. Fevre C.; Jbel M.; Passet V.; Weill F. X.; Grimont P. A.; Brisse S. Six groups of the OXY beta-Lactamase evolved over millions of years in Klebsiella oxytoca. Antimicrob Agents Chemother: 2005; 49 8 3453 3462
2. Hall B. G.; Barlow M. Structure-based phylogenies of the serine beta-lactamases. J Mol Evol: 2003; 57 3 255 260
3. Hall B. G.; Salipante S. J.; Barlow M. The metallo-beta-lactamases fall into two distinct phylogenetic groups. J Mol Evol: 2003; 57 3 249 254
4. Bhullar K.; Waglechner N.; Pawlowski A.; et al. Antibiotic resistance is prevalent in an isolated cave microbiome. PLoS ONE: 2012; 7 4 e34953
5. Abraham E. P.; Chain E. An enzyme from bacteria able to destroy penicillin. Nature: 1940; 146 3713 837
6. Jacoby G. A. AmpC beta-lactamases. Clin Microbiol Rev: 2009; 22 1 161 182
7. Bush K. Proliferation and significance of clinically relevant β-lactamases. Ann N Y Acad Sci: 2013; 1277 84 90
8. Knothe H.; Shah P.; Krcmery V.; Antal M.; Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection: 1983; 11 6 315 317
9. Mushtaq S.; Livermore D. M. AmpC induction by ceftaroline. J Antimicrob Chemother: 2010; 65 3 586 588
10. Bush K.; Jacoby G. A.; Medeiros A. A. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother: 1995; 39 6 1211 1233
11. Ambler R. P. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci: 1980; 289 1036 321 331
12. Lee J. H.; Bae I. K.; Lee S. H. New definitions of extended-spectrum β-lactamase conferring worldwide emerging antibiotic resistance. Med Res Rev: 2012; 32 1 216 232
13. Giske C. G.; Sundsfjord A. S.; Kahlmeter G.; et al. Redefining extended-spectrum beta-lactamases: balancing science and clinical need. J Antimicrob Chemother: 2009; 63 1 1 4
14. Bush K.; Jacoby G. A.; Amicosante G.; et al. Comment on: Redefining extended-spectrum beta-lactamases: balancing science and clinical need. J Antimicrob Chemother: 2009; 64 1 212 213, author reply 213-215
15. Corvec S.; Prodhomme A.; Giraudeau C.; Dauvergne S.; Reynaud A.; Caroff N. Most Escherichia coli strains overproducing chromosomal AmpC beta-lactamase belong to phylogenetic group A. J Antimicrob Chemother: 2007; 60 4 872 876
16. Jacobs C.; Frère J-M, Normark S. Cytosolic intermediates for cell wall biosynthesis and degradation control inducible β-lactam resistance in gram-negative bacteria. Cell: 1997; 88 6 823 832
17. Macdougall C. Beyond susceptible and resistant, Part I: Treatment of infections due to gram-negative organisms with inducible β-lactamases. J Pediatr Pharmacol Ther: 2011; 16 1 23 30
18. Harris P. N.; Ferguson J. K. Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents: 2012; 40 4 297 305
19. Livermore D. M. beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev: 1995; 8 4 557 584
20. Lodge J. M.; Minchin S. D.; Piddock L. J.; Busby S. J. Cloning, sequencing and analysis of the structural gene and regulatory region of the Pseudomonas aeruginosa chromosomal ampC beta-lactamase. Biochem J: 1990; 272 3 627 631
21. Lindberg F.; Normark S. Common mechanism of ampC beta-lactamase induction in enterobacteria: regulation of the cloned Enterobacter cloacae P99 beta-lactamase gene. J Bacteriol: 1987; 169 2 758 763
22. Lindberg F.; Westman L.; Normark S. Regulatory components in Citrobacter freundii ampC beta-lactamase induction. Proc Natl Acad Sci U S A: 1985; 82 14 4620 4624
23. Korfmann G.; Sanders C. C. ampG is essential for high-level expression of AmpC beta-lactamase in Enterobacter cloacae. Antimicrob Agents Chemother: 1989; 33 11 1946 1951
24. Mark B. L.; Vocadlo D. J.; Oliver A. Providing β-lactams a helping hand: targeting the AmpC β-lactamase induction pathway. Future Microbiol: 2011; 6 12 1415 1427
25. Johnson J. W.; Fisher J. F.; Mobashery S. Bacterial cell-wall recycling. Ann N Y Acad Sci: 2013; 1277 1 54 75
26. Kaneko K.; Okamoto R.; Nakano R.; Kawakami S.; Inoue M. Gene mutations responsible for overexpression of AmpC beta-lactamase in some clinical isolates of Enterobacter cloacae. J Clin Microbiol: 2005; 43 6 2955 2958
27. Sanders W. E. Jr, Sanders C. C. Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin Microbiol Rev: 1997; 10 2 220 241
28. Bauernfeind A.; Chong Y.; Schweighart S. Extended broad spectrum beta-lactamase in Klebsiella pneumoniae including resistance to cephamycins. Infection: 1989; 17 5 316 321
29. Alvarez M.; Tran J. H.; Chow N.; Jacoby G. A. Epidemiology of conjugative plasmid-mediated AmpC beta-lactamases in the United States. Antimicrob Agents Chemother: 2004; 48 2 533 537
30. Sidjabat H. E.; Seah K. Y.; Coleman L.; et al. Expansive spread of IncI1 plasmids carrying blaCMY-2 amongst Escherichia coli. Int J Antimicrob Agents: 2014; 44 3 203 208
31. Reuland E. A.; Hays J. P.; de Jongh D. M.; et al. Detection and occurrence of plasmid-mediated AmpC in highly resistant gram-negative rods. PLoS ONE: 2014; 9 3 e91396
32. Freitas F.; Machado E.; Ribeiro T. G.; Novais Â, Peixe L. Long-term dissemination of acquired AmpC β-lactamases among Klebsiella spp. and Escherichia coli in Portuguese clinical settings. Eur J Clin Microbiol Infect Dis: 2014; 33 4 551 558
33. Rodríguez-Baño J.; Miró E.; Villar M.; et al. Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC β-lactamases. J Infect: 2012; 64 2 176 183
34. Gude M. J.; Seral C.; Sáenz Y.; et al. Molecular epidemiology, resistance profiles and clinical features in clinical plasmid-mediated AmpC-producing Enterobacteriaceae. Int J Med Microbiol: 2013; 303 8 553 557
35. Hanson N. D. AmpC beta-lactamases: what do we need to know for the future? J Antimicrob Chemother: 2003; 52 1 2 4
36. Jeong S. H.; Song W.; Park M. J.; et al. Boronic acid disk tests for identification of extended-spectrum beta-lactamase production in clinical isolates of Enterobacteriaceae producing chromosomal AmpC beta-lactamases. Int J Antimicrob Agents: 2008; 31 5 467 471
37. Miriagou V.; Tzouvelekis L. S.; Villa L.; et al. CMY-13, a novel inducible cephalosporinase encoded by an Escherichia coli plasmid. Antimicrob Agents Chemother: 2004; 48 8 3172 3174
38. Rodríguez-Martínez J. M.; Fernández-Echauri P.; Fernández-Cuenca F.; Diaz de Alba P.; Briales A.; Pascual A. Genetic characterization of an extended-spectrum AmpC cephalosporinase with hydrolysing activity against fourth-generation cephalosporins in a clinical isolate of Enterobacter aerogenes selected in vivo. J Antimicrob Chemother: 2012; 67 1 64 68
39. Denisuik A. J.; Lagacé-Wiens P. R.; Pitout J. D.; et al. Canadian Antimicrobial Resistance Alliance. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5-year period: CANWARD 2007-11. J Antimicrob Chemother: 2013; 68 01 i57 i65
40. World Health Organisation Antimicrobial Resistance Global Report on Surveillance. Geneva WHO: 2014
41. Ho P. L.; Chow K. H.; Lai E. L.; Lau E. H.; Cheng V. C. Extended-spectrum-β-lactamase-positive Escherichia coli mainly adds to, rather than replaces, extended-spectrum-β-lactamase-negative E. coli in causing bacteraemia in Hong Kong, 2000-10. J Antimicrob Chemother: 2012; 67 3 778 780
42. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States: U.S. Department of Health and Human Services: 2013
43. Turnidge J.; Gottlieb T.; Mitchell D.; et al. Gram-Negative Survey 2012 Antimicrobial Susceptibility Report: Australian Group for Antimicrobial Resistance (AGAR); 2013
44. Guzmán-Blanco M.; Labarca J. A.; Villegas M. V.; Gotuzzo E.; Latin America Working Group on Bacterial Resistance. Extended spectrum β-lactamase producers among nosocomial Enterobacteriaceae in Latin America. Braz J Infect Dis: 2014; 18 4 421 433
45. Lob S. H.; Badal R. E.; Bouchillon S. K.; Hawser S. P.; Hackel M. A.; Hoban D. J. Epidemiology and susceptibility of Gram-negative appendicitis pathogens: SMART 2008-2010. Surg Infect (Larchmt): 2013; 14 2 203 208
46. Hawser S. P.; Bouchillon S. K.; Lascols C.; et al. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009). Clin Microbiol Infect: 2012; 18 3 253 259
47. Chen Y. H.; Hsueh P. R.; Badal R. E.; et al. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J Infect: 2011; 62 4 280 291
48. Ginn A. N.; Wiklendt A. M.; Zong Z.; et al. Prediction of major antibiotic resistance in Escherichia coli and Klebsiella pneumoniae in Singapore, USA and China using a limited set of gene targets. Int J Antimicrob Agents: 2014; 43 6 563 565
49. Sheng W. H.; Badal R. E.; Hsueh P. R.; SMART Program. Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother: 2013; 57 7 2981 2988
50. Pitout J. D. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs: 2010; 70 3 313 333
51. Chen L. F.; Freeman J. T.; Nicholson B.; et al. Widespread dissemination of CTX-M-15 genotype extended-spectrum-β-lactamase-producing enterobacteriaceae among patients presenting to community hospitals in the southeastern United States. Antimicrob Agents Chemother: 2014; 58 2 1200 1202
52. Petty N. K.; Ben Zakour N. L.; Stanton-Cook M.; et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A: 2014; 111 15 5694 5699
53. Rodríguez-Baño J.; Navarro M. D.; Romero L.; et al. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis: 2006; 43 11 1407 1414
54. Doi Y.; Adams J.; O'Keefe A.; Quereshi Z.; Ewan L.; Paterson D. L. Community-acquired extended-spectrum beta-lactamase producers, United States. Emerg Infect Dis: 2007; 13 7 1121 1123
55. Doi Y.; Park Y. S.; Rivera J. I.; et al. Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis: 2013; 56 5 641 648
56. Ben-Ami R.; Rodríguez-Baño J.; Arslan H.; et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis: 2009; 49 5 682 690
57. Ben-Ami R.; Schwaber M. J.; Navon-Venezia S.; et al. Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis: 2006; 42 7 925 934
58. Stuart R. L.; Kotsanas D.; Webb B.; et al. Prevalence of antimicrobial-resistant organisms in residential aged care facilities. Med J Aust: 2011; 195 9 530 533
59. Rogers B. A.; Ingram P. R.; Runnegar N.; et al. Australasian Society for Infectious Diseases Clinical Research Network. Community-onset Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countries. Antimicrob Agents Chemother: 2014; 58 4 2126 2134
60. Solé M.; Pitart C.; Oliveira I.; et al. Extended spectrum β-lactamase-producing Escherichia coli faecal carriage in Spanish travellers returning from tropical and subtropical countries. Clin Microbiol Infect: 2014
61. Valenza G.; Nickel S.; Pfeifer Y.; et al. Extended-spectrum-β-lactamase-producing Escherichia coli as intestinal colonizers in the German community. Antimicrob Agents Chemother: 2014; 58 2 1228 1230
62. Titelman E.; Hasan C. M.; Iversen A.; et al. Faecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae is common 12 months after infection and is related to strain factors. Clin Microbiol Infect: 2014; 20 8 O508 O515
63. Birgand G.; Armand-Lefevre L.; Lolom I.; Ruppe E.; Andremont A.; Lucet J. C. Duration of colonization by extended-spectrum β-lactamase-producing Enterobacteriaceae after hospital discharge. Am J Infect Control: 2013; 41 5 443 447
64. Paterson D. L.; Ko W. C.; Von Gottberg A.; et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med: 2004; 140 1 26 32
65. Rodríguez-Baño J.; Navarro M. D.; Romero L.; et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol: 2004; 42 3 1089 1094
66. Fan N. C.; Chen H. H.; Chen C. L.; et al. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children. J Microbiol Immunol Infect: 2014; 47 5 399 405
67. Kang C. I.; Kim S. H.; Kim D. M.; et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol: 2004; 25 10 860 867
68. Tumbarello M.; Spanu T.; Sanguinetti M.; et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother: 2006; 50 2 498 504
69. Park Y. S.; Bae I. K.; Kim J.; et al. Risk factors and molecular epidemiology of community-onset extended-spectrum β-lactamase-producing Escherichia coli bacteremia. Yonsei Med J: 2014; 55 2 467 475
70. Vodovar D.; Marcadé G.; Rousseau H.; et al. Predictive factors for extended-spectrum beta-lactamase producing Enterobacteriaceae causing infection among intensive care unit patients with prior colonization. Infection: 2014; 42 4 743 748
71. Du B.; Long Y.; Liu H.; et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med: 2002; 28 12 1718 1723
72. Kim Y. K.; Pai H.; Lee H. J.; et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother: 2002; 46 5 1481 1491
73. Martínez J. A.; Aguilar J.; Almela M.; et al. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia. J Antimicrob Chemother: 2006; 58 5 1082 1085
74. Freeman J. T.; McBride S. J.; Nisbet M. S.; et al. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes. Int J Infect Dis: 2012; 16 5 e371 e374
75. Wener K. M.; Schechner V.; Gold H. S.; Wright S. B.; Carmeli Y. Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients. Antimicrob Agents Chemother: 2010; 54 5 2010 2016
76. Johnson S. W.; Anderson D. J.; May D. B.; Drew R. H. Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum β-lactamase-producing enterobacteriaceae on hospital admission. Infect Control Hosp Epidemiol: 2013; 34 4 385 392
77. Slekovec C.; Bertrand X.; Leroy J.; Faller J. P.; Talon D.; Hocquet D. Identifying patients harboring extended-spectrum-β-lactamase-producing Enterobacteriaceae on hospital admission is not that simple. Antimicrob Agents Chemother: 2012; 56 4 2218 2219, author reply 2220
78. Ha Y. E.; Kang C. I.; Cha M. K.; et al. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents: 2013; 42 5 403 409
79. Kang C. I.; Chung D. R.; Ko K. S.; Peck K. R.; Song J. H.; Korean Network for Study of Infectious Diseases. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol: 2012; 91 1 115 121
80. Lautenbach E.; Patel J. B.; Bilker W. B.; Edelstein P. H.; Fishman N. O. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis: 2001; 32 8 1162 1171
81. MacVane S. H.; Tuttle L. O.; Nicolau D. P. Impact of extended-spectrum β-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. J Hosp Med: 2014; 9 4 232 238
82. Lee S.; Song Y.; Cho S. H.; Kwon K. T. Impact of extended-spectrum beta-lactamase on acute pyelonephritis treated with empirical ceftriaxone. Microb Drug Resist: 2014; 20 1 39 44
83. Stewardson A.; Fankhauser C.; De Angelis G.; et al. Burden of bloodstream infection caused by extended-spectrum β-lactamase-producing enterobacteriaceae determined using multistate modeling at a Swiss University Hospital and a nationwide predictive model. Infect Control Hosp Epidemiol: 2013; 34 2 133 143
84. Tumbarello M.; Spanu T.; Di Bidino R.; et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother: 2010; 54 10 4085 4091
85. Tumbarello M.; Sanguinetti M.; Montuori E.; et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother: 2007; 51 6 1987 1994
86. Hyle E. P.; Lipworth A. D.; Zaoutis T. E.; Nachamkin I.; Bilker W. B.; Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection. Arch Intern Med: 2005; 165 12 1375 1380
87. Apisarnthanarak A.; Mundy L. M. Prevalence, treatment, and outcome of infection due to extended-spectrum Beta-lactamase-producing microorganisms. Infect Control Hosp Epidemiol: 2006; 27 3 326 327
88. To K. K.; Lo W. U.; Chan J. F.; Tse H.; Cheng V. C.; Ho P. L. Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity. Int J Infect Dis: 2013; 17 2 e120 e124
89. Frakking F. N.; Rottier W. C.; Dorigo-Zetsma J. W.; et al. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria. Antimicrob Agents Chemother: 2013; 57 7 3092 3099
90. Wu U. I.; Chen W. C.; Yang C. S.; et al. Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis. Int J Infect Dis: 2012; 16 1 e47 e52
91. Chaubey V. P.; Pitout J. D.; Dalton B.; et al. Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. BMC Res Notes: 2010; 3 116
92. Schwaber M. J.; Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother: 2007; 60 5 913 920
93. Smith C. E.; Tillman B. S.; Howell A. W.; Longfield R. N.; Jorgensen J. H. Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum beta-lactamase. Antimicrob Agents Chemother: 1990; 34 6 1290 1293
94. Karas J. A.; Pillay D. G.; Muckart D.; Sturm A. W. Treatment failure due to extended spectrum beta-lactamase. J Antimicrob Chemother: 1996; 37 1 203 204
95. Rice L. B.; Yao J. D.; Klimm K.; Eliopoulos G. M.; Moellering R. C. Jr. Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob Agents Chemother: 1991; 35 6 1243 1244
96. Paterson D. L.; Ko W. C.; Von Gottberg A.; et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol: 2001; 39 6 2206 2212
97. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; Tenth Informational Supplement (Aerobic Dilution) M100-S10. Wayne, PA NCCLS: 2000
98. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty Third Informational Supplement. CLSI Document M100-S23. Wayne, PA CLSI: 2013
99. European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters Version 3.1; 2013. Available at: http://www.eucast.org
100. Kang C. I.; Cha M. K.; Kim S. H.; et al. Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria. Int J Antimicrob Agents: 2014; 43 5 456 459
101. Leclercq R.; Cantón R.; Brown D. F.; et al. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect: 2013; 19 2 141 160
102. Livermore D. M.; Andrews J. M.; Hawkey P. M.; et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother: 2012; 67 7 1569 1577
103. Chow J. W.; Fine M. J.; Shlaes D. M.; et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med: 1991; 115 8 585 590
104. Kaye K. S.; Cosgrove S.; Harris A.; Eliopoulos G. M.; Carmeli Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother: 2001; 45 9 2628 2630
105. Choi S. H.; Lee J. E.; Park S. J.; et al. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother: 2008; 52 3 995 1000
106. Cosgrove S. E.; Kaye K. S.; Eliopoulous G. M.; Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med: 2002; 162 2 185 190
107. Livermore D. M.; Brown D. F.; Quinn J. P.; Carmeli Y.; Paterson D. L.; Yu V. L. Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae? Clin Microbiol Infect: 2004; 10 1 84 85
108. Pai H.; Kang C. I.; Byeon J. H.; et al. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother: 2004; 48 10 3720 3728
109. Sanders W. E. Jr, Tenney J. H.; Kessler R. E. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis: 1996; 23 3 454 461
110. Tamma P. D.; Girdwood S. C.; Gopaul R.; et al. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae. Clin Infect Dis: 2013; 57 6 781 788
111. Siedner M. J.; Galar A.; Guzmán-Suarez B. B.; et al. Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clin Infect Dis: 2014; 58 11 1554 1563
112. Choi S. H.; Lee J. E.; Park S. J.; et al. Prevalence, microbiology, and clinical characteristics of extended-spectrum beta-lactamase-producing Enterobacter spp.; Serratia marcescens, Citrobacter freundii, and Morganella morganii in Korea. Eur J Clin Microbiol Infect Dis: 2007; 26 8 557 561
113. Gottlieb T.; Wolfson C. Comparison of the MICs of cefepime for extended-spectrum beta-lactamase-producing and non-extended-spectrum beta-lactamase-producing strains of Enterobacter cloacae. J Antimicrob Chemother: 2000; 46 2 330 331
114. Bhat S. V.; Peleg A. Y.; Lodise T. P. Jr.; et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother: 2007; 51 12 4390 4395
115. Burgess D. S.; Hall R. G. II. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis: 2004; 49 1 41 46
116. Thomson K. S.; Moland E. S. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother: 2001; 45 12 3548 3554
117. Kang C. I.; Pai H.; Kim S. H.; et al. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase. J Antimicrob Chemother: 2004; 54 6 1130 1133
118. Fernández-Cuenca F.; Rodríguez-Martínez J. M.; Martínez-Martínez L.; Pascual A. In vivo selection of Enterobacter aerogenes with reduced susceptibility to cefepime and carbapenems associated with decreased expression of a 40 kDa outer membrane protein and hyperproduction of AmpC beta-lactamase. Int J Antimicrob Agents: 2006; 27 6 549 552
119. Labombardi V. J.; Rojtman A.; Tran K. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Diagn Microbiol Infect Dis: 2006; 56 3 313 315
120. Lee N. Y.; Lee C. C.; Huang W. H.; Tsui K. C.; Hsueh P. R.; Ko W. C. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis: 2013; 56 4 488 495
121. Chopra T.; Marchaim D.; Veltman J.; et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother: 2012; 56 7 3936 3942
122. Nguyen H. M.; Shier K. L.; Graber C. J. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother: 2014; 69 4 871 880
123. Rhodes N. J.; Richardson C. L.; Heraty R.; et al. Unacceptably high error rates in Vitek 2 testing of cefepime susceptibility in extended spectrum? lactamase producing Escherichia coli. Antimicrob Agents Chemother: 2014; 58 7 3757 3761
124. Lepeule R.; Ruppé E.; Le P.; et al. Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase. Antimicrob Agents Chemother: 2012; 56 3 1376 1381
125. Doi A.; Shimada T.; Harada S.; Iwata K.; Kamiya T. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Infect Dis: 2013; 17 3 e159 e163
126. Yang C. C.; Li S. H.; Chuang F. R.; et al. Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis. BMC Infect Dis: 2012; 12 206
127. Kiffer C. R.; Kuti J. L.; Eagye K. J.; Mendes C.; Nicolau D. P. Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil. Int J Antimicrob Agents: 2006; 28 4 340 344
128. Paterson D. L.; Ko W. C.; Von Gottberg A.; et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis: 2004; 39 1 31 37
129. Collins V. L.; Marchaim D.; Pogue J. M.; et al. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother: 2012; 56 4 2173 2177
130. Pitout J. D.; Laupland K. B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis: 2008; 8 3 159 166
131. Vardakas K. Z.; Tansarli G. S.; Rafailidis P. I.; Falagas M. E. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother: 2012; 67 12 2793 2803
132. DeRyke C. A.; Banevicius M. A.; Fan H. W.; Nicolau D. P. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother: 2007; 51 4 1481 1486
133. Bassetti M.; Righi E.; Fasce R.; et al. Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit. J Antimicrob Chemother: 2007; 60 2 433 435
134. Fong J. J.; Rosé L.; Radigan E. A. Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum β-lactamase producing gram-negative bacteria. Ann Pharmacother: 2012; 46 3 347 352
135. Lye D. C.; Wijaya L.; Chan J.; Teng C. P.; Leo Y. S. Ertapenem for treatment of extended-spectrum beta-lactamase-producing and multidrug-resistant gram-negative bacteraemia. Ann Acad Med Singapore: 2008; 37 10 831 834
136. Lee N. Y.; Huang W. H.; Tsui K. C.; Hsueh P. R.; Ko W. C. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae. Diagn Microbiol Infect Dis: 2011; 70 1 150 153
137. Huang S. S.; Lee M. H.; Leu H. S. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella. J Microbiol Immunol Infect: 2006; 39 496 502
138. Qureshi Z. A.; Paterson D. L.; Pakstis D. L.; et al. Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections. Int J Antimicrob Agents: 2011; 37 1 26 32
139. Lee C. C.; Lee N. Y.; Yan J. J.; et al. Bacteremia due to extended-spectrum-beta-lactamase-producing Enterobacter cloacae: role of carbapenem therapy. Antimicrob Agents Chemother: 2010; 54 9 3551 3556
140. Elliott E.; Brink A. J.; van Greune J.; et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. Clin Infect Dis: 2006; 42 11 e95 e98
141. Szabó D.; Silveira F.; Hujer A. M.; et al. Outer membrane protein changes and efflux pump expression together may confer resistance to ertapenem in Enterobacter cloacae. Antimicrob Agents Chemother: 2006; 50 8 2833 2835
142. Suh B.; Bae I. K.; Kim J.; Jeong S. H.; Yong D.; Lee K. Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss. Antimicrob Agents Chemother: 2010; 54 12 5057 5061
143. Skurnik D.; Lasocki S.; Bremont S.; et al. Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extended-spectrum beta-lactamase. J Med Microbiol: 2010; 59 Pt 1 115 119
144. Guillon H.; Tande D.; Mammeri H. Emergence of ertapenem resistance in an Escherichia coli clinical isolate producing extended-spectrum beta-lactamase AmpC. Antimicrob Agents Chemother: 2011; 55 9 4443 4446
145. Mammeri H.; Nordmann P.; Berkani A.; Eb F. Contribution of extended-spectrum AmpC (ESAC) beta-lactamases to carbapenem resistance in Escherichia coli. FEMS Microbiol Lett: 2008; 282 2 238 240
146. European Committee on Antimicrobial Susceptibility Testing. EUCAST Guidelines for Detection of Resistance Mechanisms and Specific Resistances of Clinical and/or Epidemiological Importance. 2012. Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Consultation/ (Accessed June 2014)
147. Lister P. D. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa. Pharmacotherapy: 2000; 20 9, Pt 2 213S 218S, discussion 224S-228S
148. Paterson D. L.; Bonomo R. A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev: 2005; 18 4 657 686
149. Pagani L.; Migliavacca R.; Luzzaro F.; et al. Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae. Chemotherapy: 1998; 44 6 377 384
150. Canoui E.; Tankovic J.; Bige N.; Alves M.; Offenstadt G. Which proportion of extended-spectrum beta-lactamase producing strains could be treated by non-carbapenem beta-lactams? Med Mal Infect: 2014; 44 5 235 237
151. López-Cerero L.; Picón E.; Morillo C.; et al. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. Clin Microbiol Infect: 2010; 16 2 132 136
152. Craig W. A.; Bhavnani S. M.; Ambrose P. G. The inoculum effect: fact or artifact? Diagn Microbiol Infect Dis: 2004; 50 4 229 230
153. Docobo-Pérez F.; López-Cerero L.; López-Rojas R.; et al. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model. Antimicrob Agents Chemother: 2013; 57 5 2109 2113
154. Harada Y.; Morinaga Y.; Kaku N.; et al. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae. Clin Microbiol Infect: 2014; 20 11 831 839 [epub ahead of print]
155. Thauvin-Eliopoulos C.; Tripodi M. F.; Moellering R. C. Jr, Eliopoulos G. M. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother: 1997; 41 5 1053 1057
156. Akhan S.; Coskunkan F.; Tansel O.; Vahaboglu H. Conjugative resistance to tazobactam plus piperacillin among extended-spectrum beta-lactamase-producing nosocomial Klebsiella pneumoniae. Scand J Infect Dis: 2001; 33 7 512 515
157. Perez F.; Bonomo R. A. Can we really use β-lactam/β-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum β-lactamase-producing bacteria? Clin Infect Dis: 2012; 54 2 175 177
158. Livermore D. M.; Hope R.; Mushtaq S.; Warner M. Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers. Clin Microbiol Infect: 2008; 14 01 189 193
159. Paterson D. L.; Singh N.; Gayowski T.; Marino I. R. Fatal infection due to extended-spectrum beta-lactamase-producing Escherichia coli: implications for antibiotic choice for spontaneous bacterial peritonitis. Clin Infect Dis: 1999; 28 3 683 684
160. Zimhony O.; Chmelnitsky I.; Bardenstein R.; et al. Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother: 2006; 50 9 3179 3182
161. Essack S. Y. Treatment options for extended-spectrum beta-lactamase-producers. FEMS Microbiol Lett: 2000; 190 2 181 184
162. Gavin P. J.; Suseno M. T.; Thomson R. B. Jr.; et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother: 2006; 50 6 2244 2247
163. Apisarnthanarak A.; Kiratisin P.; Saifon P.; Kitphati R.; Dejsirilert S.; Mundy L. M. Risk factors for and outcomes of healthcare-associated infection due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae in Thailand. Infect Control Hosp Epidemiol: 2007; 28 7 873 876
164. Kang C. I.; Park S. Y.; Chung D. R.; Peck K. R.; Song J. H. Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Infect: 2012; 64 5 533 534
165. Peralta G.; Lamelo M.; Alvarez-García P.; et al. SEMI-BLEE STUDY GROUP. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study. BMC Infect Dis: 2012; 12 245
166. Rodríguez-Baño J.; Navarro M. D.; Retamar P.; Picón E.; Pascual Á.; Extended-Spectrum Beta-Lactamases-Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis: 2012; 54 2 167 174
167. Retamar P.; López-Cerero L.; Muniain M. A.; Pascual Á, Rodríguez-Baño J.; ESBL-REIPI/GEIH Group. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother: 2013; 57 7 3402 3404
168. Gutiérrez-Gutiérrez B.; Salamanca E.; Pérez-Galera S.; et al. Assessment of Beta-Lactam/Beta-Lactamase Inhibitor Combinations for the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae: The INCREMENT Project. Washington, DC ICAAC: 2014
169. Felton T. W.; Roberts J. A.; Lodise T. P.; et al. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy. Antimicrob Agents Chemother: 2014; 58 7 4094 4102
170. Carlier M.; Carrette S.; Roberts J. A.; et al. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care: 2013; 17 3 R84
171. Dulhunty J. M.; Roberts J. A.; Davis J. S.; et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis: 2013; 56 2 236 244
172. Bush K.; Macalintal C.; Rasmussen B. A.; Lee V. J.; Yang Y. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother: 1993; 37 4 851 858
173. Akova M.; Yang Y.; Livermore D. M. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases. J Antimicrob Chemother: 1990; 25 2 199 208
174. Power P.; Galleni M.; Ayala J. A.; Gutkind G. Biochemical and molecular characterization of three new variants of AmpC beta-lactamases from Morganella morganii. Antimicrob Agents Chemother: 2006; 50 3 962 967
175. Marcos M.; Iñurrieta A.; Soriano A.; et al. Effect of antimicrobial therapy on mortality in 377 episodes of Enterobacter spp. bacteraemia. J Antimicrob Chemother: 2008; 62 2 397 403
176. Schwaber M. J.; Graham C. S.; Sands B. E.; Gold H. S.; Carmeli Y. Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species. Antimicrob Agents Chemother: 2003; 47 6 1882 1886
177. Falagas M. E.; Kastoris A. C.; Kapaskelis A. M.; Karageorgopoulos D. E. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis: 2010; 10 1 43 50
178. de Cueto M.; López L.; Hernández J. R.; Morillo C.; Pascual A. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother: 2006; 50 1 368 370
179. Nakamura T.; Komatsu M.; Yamasaki K.; et al. Susceptibility of various oral antibacterial agents against extended spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae. J Infect Chemother: 2014; 20 1 48 51
180. Morfín-Otero R.; Mendoza-Olazarán S.; Silva-Sánchez J.; et al. Characterization of Enterobacteriaceae isolates obtained from a tertiary care hospital in Mexico, which produces extended-spectrum β-lactamase. Microb Drug Resist: 2013; 19 5 378 383
181. Gupta V.; Rani H.; Singla N.; Kaistha N.; Chander J. Determination of Extended-Spectrum β-Lactamases and AmpC Production in Uropathogenic Isolates of Escherichia coli and Susceptibility to Fosfomycin. J Lab Physicians: 2013; 5 2 90 93
182. Hutley E. J.; Chand M. A.; Hounsome G.; Kelsey M. C. Fosfomycin: an oral agent for urinary infection caused by extended spectrum beta-lactamase producing organisms. J Infect: 2010; 60 4 308 309
183. Auer S.; Wojna A.; Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother: 2010; 54 9 4006 4008
184. Wilson D. T.; May D. B. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Am J Ther: 2013; 20 6 685 690
185. Senol S.; Tasbakan M.; Pullukcu H.; et al. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J Chemother: 2010; 22 5 355 357
186. Gardiner B. J.; Mahony A. A.; Ellis A. G.; et al. Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis: 2014; 58 4 e101 e105
187. Rodríguez-Avial C.; Rodríguez-Avial I.; Hernández E.; Picazo J. J. Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011) [in Spanish]. Rev Esp Quimioter: 2013; 26 1 43 46
188. Ellington M. J.; Livermore D. M.; Pitt T. L.; Hall L. M.; Woodford N. Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance. J Antimicrob Chemother: 2006; 58 4 848 852
189. Lee S. Y.; Park Y. J.; Yu J. K.; et al. Prevalence of acquired fosfomycin resistance among extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3. J Antimicrob Chemother: 2012; 67 12 2843 2847
190. Corvec S.; Furustrand Tafin U.; Betrisey B.; Borens O.; Trampuz A. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model. Antimicrob Agents Chemother: 2013; 57 3 1421 1427
191. Lee W. S.; Wang F. D.; Shieh Y. H.; Teng S. O.; Ou T. Y. Lemierre syndrome complicating multiple brain abscesses caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae cured by fosfomycin and meropenem combination therapy. J Microbiol Immunol Infect: 2012; 45 1 72 74
192. Falagas M. E.; Giannopoulou K. P.; Kokolakis G. N.; Rafailidis P. I. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis: 2008; 46 7 1069 1077
193. Silva-Sanchez J.; Reyna-Flores F.; Velazquez-Meza M. E.; Rojas-Moreno T.; Benitez-Diaz A.; Sanchez-Perez A.; Study Group. In vitro activity of tigecycline against extended-spectrum β-lactamase-producing Enterobacteriaceae and MRSA clinical isolates from Mexico: a multicentric study. Diagn Microbiol Infect Dis: 2011; 70 2 270 273
194. Geerlings S. E.; van Donselaar-van der Pant K. A.; Keur I. Successful treatment with tigecycline of two patients with complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother: 2010; 65 9 2048 2049
195. Cho S. Y.; Kang C. I.; Chung D. R.; Peck K. R.; Song J. H.; Jang J. H. Breakthrough bacteremia due to extended-spectrum-β-lactamase-producing Klebsiella pneumoniae during combination therapy with colistin and tigecycline. Antimicrob Agents Chemother: 2012; 56 9 4994 4995, author reply 4996
196. Chen P. L.; Yan J. J.; Wu C. J.; et al. Salvage therapy with tigecycline for recurrent infection caused by ertapenem-resistant extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis: 2010; 68 3 312 314
197. Prasad P.; Sun J.; Danner R. L.; Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis: 2012; 54 12 1699 1709
198. Neu H. C. Mecillinam-an amidino penicillin which acts synergistically with other β-lactam compounds. J Antimicrob Chemother: 1977; 3 (Suppl B): 43 52
199. Gupta K.; Hooton T. M.; Naber K. G.; et al. Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis: 2011; 52 5 e103 e120
200. Brenwald N. P.; Andrews J.; Fraise A. P. Activity of mecillinam against AmpC beta-lactamase-producing Escherichia coli. J Antimicrob Chemother: 2006; 58 1 223 224
201. Lampri N.; Galani I.; Poulakou G.; et al. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. J Antimicrob Chemother: 2012; 67 10 2424 2428
202. Wootton M.; Walsh T. R.; Macfarlane L.; Howe R. A. Activity of mecillinam against Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother: 2010; 65 1 79 81
203. Sougakoff W.; Jarlier V. Comparative potency of mecillinam and other β-lactam antibiotics against Escherichia coli strains producing different β-lactamases. J Antimicrob Chemother: 2000; 46 01 9 14
204. Titelman E.; Iversen A.; Kalin M.; Giske C. G. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist: 2012; 18 2 189 192
205. Poulsen H. O.; Johansson A.; Granholm S.; Kahlmeter G.; Sundqvist M. High genetic diversity of nitrofurantoin- or mecillinam-resistant Escherichia coli indicates low propensity for clonal spread. J Antimicrob Chemother: 2013; 68 9 1974 1977
206. Rodriguez-Villalobos H.; Malaviolle V.; Frankard J.; de Mendonça R.; Nonhoff C.; Struelens M. J. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother: 2006; 57 4 771 774
207. Livermore D. M.; Hope R.; Fagan E. J.; Warner M.; Woodford N.; Potz N. Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. J Antimicrob Chemother: 2006; 57 5 1012 1014
208. Balakrishnan I.; Awad-El-Kariem F. M.; Aali A.; et al. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother: 2011; 66 11 2628 2631
209. Fournier D.; Chirouze C.; Leroy J.; et al. Alternatives to carbapenems in ESBL-producing Escherichia coli infections. Med Mal Infect: 2013; 43 2 62 66
210. Tasbakan M. I.; Pullukcu H.; Sipahi O. R.; Yamazhan T.; Ulusoy S. Nitrofurantoin in the treatment of extended-spectrum β-lactamase-producing Escherichia coli-related lower urinary tract infection. Int J Antimicrob Agents: 2012; 40 6 554 556
211. Endimiani A.; Luzzaro F.; Perilli M.; et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis: 2004; 38 2 243 251
212. Farrell D. J.; Sader H. S.; Flamm R. K.; Jones R. N. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents: 2014; 43 6 533 539
213. Zhanel G. G.; Chung P.; Adam H.; et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs: 2014; 74 1 31 51
214. Drawz S. M.; Papp-Wallace K. M.; Bonomo R. A. New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother: 2014; 58 4 1835 1846
215. Porres-Osante N.; Dupont H.; Torres C.; Ammenouche N.; de Champs C.; Mammeri H. Avibactam activity against extended-spectrum AmpC β-lactamases. J Antimicrob Chemother: 2014; 69 6 1715 1716
216. Miossec C.; Claudon M.; Levasseur P.; Black M. T. The β-lactamase inhibitor avibactam (NXL104) does not induce ampC β-lactamase in Enterobacter cloacae. Infect Drug Resist: 2013; 6 235 240
217. Flamm R. K.; Farrell D. J.; Sader H. S.; Jones R. N. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). J Antimicrob Chemother: 2014; 69 6 1589 1598
218. Glasner C.; Albiger B.; Buist G.; et al. European Survey on Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill: 2013; 18 28 20525
219. Molton J. S.; Tambyah P. A.; Ang B. S.; Ling M. L.; Fisher D. A. The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia. Clin Infect Dis: 2013; 56 9 1310 1318
220. Nordmann P.; Dortet L.; Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med: 2012; 18 5 263 272
221. Lister P. D.; Wolter D. J.; Hanson N. D. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev: 2009; 22 4 582 610
222. Zeng X.; Lin J. Beta-lactamase induction and cell wall metabolism in Gram-negative bacteria. Front Microbiol: 2013; 4 128